메뉴 건너뛰기




Volumn 25, Issue 12, 2009, Pages 1033-1037

Recombinant proteins or monoclonal antibodies: Comparative properties and interest in rheumatoid arthritis;Protéine de fusion ou anticorps monoclonal: Quel biomédicament choisir dans une maladie inflammatoire?

Author keywords

[No Author keywords available]

Indexed keywords


EID: 74749101362     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925121033     Document Type: Review
Times cited : (5)

References (49)
  • 1
    • 0035932519 scopus 로고    scopus 로고
    • Cytokine pathways and joint inflammation in rheumatoid arthritis
    • Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001 ; 344 : 907-16.
    • (2001) N Engl J Med , vol.344 , pp. 907-916
    • Choy, E.H.1    Panayi, G.S.2
  • 2
    • 0028204113 scopus 로고
    • Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody
    • Haak-Frendscho M, Marsters SA, Mordenti J, et al. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. J Immunol 1994 ; 152 : 1347-53.
    • (1994) J Immunol , vol.152 , pp. 1347-1353
    • Haak-Frendscho, M.1    Marsters, S.A.2    Mordenti, J.3
  • 3
    • 0037842864 scopus 로고    scopus 로고
    • Geneva Sepsis Network. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis
    • Butty VL, Roux-Lombard P, Garbino J, et al. Geneva Sepsis Network. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis. Eur Cytokine Netw 2003 ; 14 : 15-9.
    • (2003) Eur Cytokine Netw , vol.14 , pp. 15-19
    • Butty, V.L.1    Roux-Lombard, P.2    Garbino, J.3
  • 4
    • 0035100346 scopus 로고    scopus 로고
    • Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
    • Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001 ; 29 : 503-10.
    • (2001) Crit Care Med , vol.29 , pp. 503-510
    • Abraham, E.1    Laterre, P.F.2    Garbino, J.3
  • 5
    • 12444335752 scopus 로고    scopus 로고
    • Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): A double blind, placebo controlled dose-finding study in rheumatoid arthritis
    • Rau R, Sander O, van Riel P, et al. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. J Rheumatol 2003 ; 30 : 680-90.
    • (2003) J Rheumatol , vol.30 , pp. 680-690
    • Rau, R.1    Sander, O.2    van Riel, P.3
  • 6
    • 0033546665 scopus 로고    scopus 로고
    • results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group
    • TNF neutralization in MS
    • TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999 ; 53 : 457-65.
    • (1999) Neurology , vol.53 , pp. 457-465
  • 7
    • 38349175313 scopus 로고    scopus 로고
    • Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content
    • Keck R, Nayak N, Lerner L, et al. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals 2008 ; 36 : 49-60.
    • (2008) Biologicals , vol.36 , pp. 49-60
    • Keck, R.1    Nayak, N.2    Lerner, L.3
  • 8
    • 0028043394 scopus 로고
    • Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis
    • Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J. Exp Med 1994 ; 180 : 2173-9.
    • (1994) J. Exp Med , vol.180 , pp. 2173-2179
    • Evans, T.J.1    Moyes, D.2    Carpenter, A.3
  • 9
    • 33749351732 scopus 로고    scopus 로고
    • rd, Bendele AM, Reznikov LI, et al. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. Arthritis Rheum 2006 ; 54 : 2872-85.
    • rd, Bendele AM, Reznikov LI, et al. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. Arthritis Rheum 2006 ; 54 : 2872-85.
  • 10
    • 35948934705 scopus 로고    scopus 로고
    • Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity
    • Davis PM, Abraham R, Xu L, et al. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 2007 ; 34 : 2204-10.
    • (2007) J Rheumatol , vol.34 , pp. 2204-2210
    • Davis, P.M.1    Abraham, R.2    Xu, L.3
  • 11
    • 23944502334 scopus 로고    scopus 로고
    • Costimulation blockade with belatacept in renal transplantation
    • Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005 ; 353 : 770-81.
    • (2005) N Engl J Med , vol.353 , pp. 770-781
    • Vincenti, F.1    Larsen, C.2    Durrbach, A.3
  • 12
    • 20044386299 scopus 로고    scopus 로고
    • Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-lg with potent immunosuppressive properties
    • Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-lg with potent immunosuppressive properties. Am J Transplant 2005 ; 5 : 443-53.
    • (2005) Am J Transplant , vol.5 , pp. 443-453
    • Larsen, C.P.1    Pearson, T.C.2    Adams, A.B.3
  • 13
    • 38549176118 scopus 로고    scopus 로고
    • Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
    • Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008 ; 117 : 244-79.
    • (2008) Pharmacol Ther , vol.117 , pp. 244-279
    • Tracey, D.1    Klareskog, L.2    Sasso, E.H.3
  • 14
    • 33750608851 scopus 로고    scopus 로고
    • Tumor necrosis factor antagonists: Different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection
    • Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006 ; 36 : 159-67.
    • (2006) Semin Arthritis Rheum , vol.36 , pp. 159-167
    • Furst, D.E.1    Wallis, R.2    Broder, M.3    Beenhouwer, D.O.4
  • 15
    • 67650096563 scopus 로고    scopus 로고
    • Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry
    • Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry. Arthritis Rneum 2009 ; 60 : 1884-94.
    • (2009) Arthritis Rneum , vol.60 , pp. 1884-1894
    • Tubach, F.1    Salmon, D.2    Ravaud, P.3
  • 16
    • 0036229932 scopus 로고    scopus 로고
    • Binding and functional comparisons of two types of tumor necrosis factor antagonists
    • Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002 ; 301 : 418-26.
    • (2002) J Pharmacol Exp Ther , vol.301 , pp. 418-426
    • Scallon, B.1    Cai, A.2    Solowski, N.3
  • 17
    • 38549145742 scopus 로고    scopus 로고
    • Comparison of certolizumab pegol, etanercept, adalimumab and infliximab : Effect on lipopolysaccharide-induced cytokine production by human peripheral blood monocytes
    • Nesbitt AM, Fossati G, Brown DT. Comparison of certolizumab pegol, etanercept, adalimumab and infliximab : effect on lipopolysaccharide-induced cytokine production by human peripheral blood monocytes. Am J Gastroenterol 2006 ; 101 : S420-70.
    • (2006) Am J Gastroenterol , vol.101
    • Nesbitt, A.M.1    Fossati, G.2    Brown, D.T.3
  • 18
    • 63749093322 scopus 로고    scopus 로고
    • Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
    • Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009 ; 131 : 308-16.
    • (2009) Clin Immunol , vol.131 , pp. 308-316
    • Kaymakcalan, Z.1    Sakorafas, P.2    Bose, S.3
  • 19
    • 34249651994 scopus 로고    scopus 로고
    • Neutralization of soluble and membrane tumor necrosis factor-alpha (TNF-alpha) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-alpha receptor specific bioassays
    • Gramlick A, Fossati G, Nesbitt AM. Neutralization of soluble and membrane tumor necrosis factor-alpha (TNF-alpha) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-alpha receptor specific bioassays. Gastroenterology 2006 ; 130 : A697.
    • (2006) Gastroenterology , vol.130
    • Gramlick, A.1    Fossati, G.2    Nesbitt, A.M.3
  • 20
    • 38549139927 scopus 로고    scopus 로고
    • Differential TNF-neutralizing potencies of adalimumab, etanercept and infliximab
    • Kaymakcalan Z, Kalghatgi L, Xiong L. Differential TNF-neutralizing potencies of adalimumab, etanercept and infliximab. Ann Rheum Dis 2006 ; 65 : 458.
    • (2006) Ann Rheum Dis , vol.65 , pp. 458
    • Kaymakcalan, Z.1    Kalghatgi, L.2    Xiong, L.3
  • 21
    • 0035910751 scopus 로고    scopus 로고
    • Uncoupling the pro-inflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: Implications for pathogenesis and therapy of autoimmune demyelination
    • Kassiotis G, Kollias G. Uncoupling the pro-inflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001 ; 193 : 427-34.
    • (2001) J Exp Med , vol.193 , pp. 427-434
    • Kassiotis, G.1    Kollias, G.2
  • 22
    • 42449093177 scopus 로고    scopus 로고
    • Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade
    • Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008 ; 58 : 947-52.
    • (2008) Arthritis Rheum , vol.58 , pp. 947-952
    • Wallis, R.S.1
  • 23
    • 0036533564 scopus 로고    scopus 로고
    • Transmembrane TNF induces on efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha
    • Olleros ML, Guler R, Corazza N, et al. Transmembrane TNF induces on efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 2002 ; 168 : 3394-401.
    • (2002) J Immunol , vol.168 , pp. 3394-3401
    • Olleros, M.L.1    Guler, R.2    Corazza, N.3
  • 24
    • 17044368806 scopus 로고    scopus 로고
    • Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection
    • Saunders BM, Tran S, Ruuls S, et al. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 2005 ; 174 : 4852-9.
    • (2005) J Immunol , vol.174 , pp. 4852-4859
    • Saunders, B.M.1    Tran, S.2    Ruuls, S.3
  • 25
    • 34249274905 scopus 로고    scopus 로고
    • Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis
    • Zhao X, Mohaupt M, Jiang J, et al. Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis. Cancer Res 2007 ; 67 : 4443-50.
    • (2007) Cancer Res , vol.67 , pp. 4443-4450
    • Zhao, X.1    Mohaupt, M.2    Jiang, J.3
  • 26
    • 14944382276 scopus 로고    scopus 로고
    • Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha
    • Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005 ; 128 : 376-92.
    • (2005) Gastroenterology , vol.128 , pp. 376-392
    • Mitoma, H.1    Horiuchi, T.2    Hatta, N.3
  • 27
    • 4644314072 scopus 로고    scopus 로고
    • Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes
    • Kirchner S, Holler E, Haffner S, et al. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 2004 ; 28 : 67-74.
    • (2004) Cytokine , vol.28 , pp. 67-74
    • Kirchner, S.1    Holler, E.2    Haffner, S.3
  • 28
    • 0028811230 scopus 로고
    • Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration
    • Suffredini AF, Redo D, Banks SM, et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995 ; 155 : 5038-45.
    • (1995) J Immunol , vol.155 , pp. 5038-5045
    • Suffredini, A.F.1    Redo, D.2    Banks, S.M.3
  • 29
    • 22744453628 scopus 로고    scopus 로고
    • + T cells against human microvascular endothelial cells
    • + T cells against human microvascular endothelial cells. Immunology 2005 ; 115 : 536-43.
    • (2005) Immunology , vol.115 , pp. 536-543
    • Vudattu, N.K.1    Holler, E.2    Ewing, P.3
  • 30
    • 0038047689 scopus 로고    scopus 로고
    • Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease
    • Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003 ; 124 : 1774-85.
    • (2003) Gastroenterology , vol.124 , pp. 1774-1785
    • Van den Brande, J.M.1    Braat, H.2    van den Brink, G.R.3
  • 31
    • 0029004771 scopus 로고
    • Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
    • Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995 ; 7 : 251-9.
    • (1995) Cytokine , vol.7 , pp. 251-259
    • Scallon, B.J.1    Moore, M.A.2    Trinh, H.3
  • 32
    • 0036278884 scopus 로고    scopus 로고
    • Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis
    • Ten Hove T, van den Blink B, Pronk I, et al. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002 ; 50 : 507-12.
    • (2002) Gut , vol.50 , pp. 507-512
    • Ten Hove, T.1    van den Blink, B.2    Pronk, I.3
  • 33
    • 0034754480 scopus 로고    scopus 로고
    • Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
    • Lügering A, Schmidt M, Lügering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001 ; 121 : 1145-57.
    • (2001) Gastroenterology , vol.121 , pp. 1145-1157
    • Lügering, A.1    Schmidt, M.2    Lügering, N.3
  • 34
    • 12344297311 scopus 로고    scopus 로고
    • Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report
    • Catrina AI, Trollmo C, Klint E, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005 ; 52 : 61-72.
    • (2005) Arthritis Rheum , vol.52 , pp. 61-72
    • Catrina, A.I.1    Trollmo, C.2    Klint, E.3
  • 35
    • 33645064086 scopus 로고    scopus 로고
    • In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab and certolizumab pegol (CDO870)
    • Fossati G, Nesbitt AM. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab and certolizumab pegol (CDO870). Am J Gastroenterol 2005 ; 100 : S299.
    • (2005) Am J Gastroenterol , vol.100
    • Fossati, G.1    Nesbitt, A.M.2
  • 36
    • 33748924118 scopus 로고    scopus 로고
    • Etanercept induces apoptosis of dermal dendritic celts in psoriatic plaques of responding patients
    • Malaviya R, Sun Y, Tan JK, et al. Etanercept induces apoptosis of dermal dendritic celts in psoriatic plaques of responding patients. J Am Acad Dermatol 2006 ; 55 : 590-7.
    • (2006) J Am Acad Dermatol , vol.55 , pp. 590-597
    • Malaviya, R.1    Sun, Y.2    Tan, J.K.3
  • 37
    • 1342285692 scopus 로고    scopus 로고
    • Tumor necrosis factor: An apoptosis
    • Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell 2004 ; 116 : 491-7.
    • (2004) JuNKie? Cell , vol.116 , pp. 491-497
    • Varfolomeev, E.E.1    Ashkenazi, A.2
  • 38
    • 38549083015 scopus 로고    scopus 로고
    • Anti-TNF antibody induced stimulated T lymphocyte apoptosis depends on the concentration of the antibody and etanercept induces apoptosis at rates equivalent to infliximab and adalimumab at 10 micrograms per ml concentration
    • Chaudhary R, Butler M, Playford RJ, Gosh S. Anti-TNF antibody induced stimulated T lymphocyte apoptosis depends on the concentration of the antibody and etanercept induces apoptosis at rates equivalent to infliximab and adalimumab at 10 micrograms per ml concentration. Gastroenterology 2007 ; 130 : A696.
    • (2007) Gastroenterology , vol.130
    • Chaudhary, R.1    Butler, M.2    Playford, R.J.3    Gosh, S.4
  • 39
    • 33747024759 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor therapy in rheumatoid arthritis alters B lymphocyte dynamics
    • Anolik JH, Owen T, Barnard J, Sanz I. Anti-tumor necrosis factor therapy in rheumatoid arthritis alters B lymphocyte dynamics. Arthritis Rheum 2005 ; 52 : S677.
    • (2005) Arthritis Rheum , vol.52
    • Anolik, J.H.1    Owen, T.2    Barnard, J.3    Sanz, I.4
  • 40
    • 26844535736 scopus 로고    scopus 로고
    • Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response
    • Han S, Zhang X, Marinova E, et al. Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response. Arthritis Rheum 2005 ; 52 : 3202-9.
    • (2005) Arthritis Rheum , vol.52 , pp. 3202-3209
    • Han, S.1    Zhang, X.2    Marinova, E.3
  • 41
    • 17044418491 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of TNF antagonists: How do they differ?
    • Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 2005 ; 34 : 12-8.
    • (2005) Semin Arthritis Rheum , vol.34 , pp. 12-18
    • Nestorov, I.1
  • 42
    • 17644386569 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of etanercept: A fully humanized soluble recombinant tumor necrosis factor receptor fusion protein
    • Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 2005 ; 45 : 490-7.
    • (2005) J Clin Pharmacol , vol.45 , pp. 490-497
    • Zhou, H.1
  • 43
    • 8644234910 scopus 로고    scopus 로고
    • Antibody pharmacokinetics and pharmacodynamics
    • Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004 ; 93 : 2645-68.
    • (2004) J Pharm Sci , vol.93 , pp. 2645-2668
    • Lobo, E.D.1    Hansen, R.J.2    Balthasar, J.P.3
  • 44
    • 38549168251 scopus 로고    scopus 로고
    • Differences in Fc receptor and C1q binding in tumor necrosis factor (TNF) antagonists may contribute to differences in mechanisms of action
    • Kohno T, Louie JS, Stevens SR. Differences in Fc receptor and C1q binding in tumor necrosis factor (TNF) antagonists may contribute to differences in mechanisms of action. J Invest Dermatol 2005 ; 124 : A111.
    • (2005) J Invest Dermatol , vol.124
    • Kohno, T.1    Louie, J.S.2    Stevens, S.R.3
  • 45
    • 33746773036 scopus 로고    scopus 로고
    • Tumor-necrosis-factor blockers: Differential effects on mycobacterial immunity
    • Saliu OY, Sofer C, Stein DS, et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006 ; 194 : 486-92.
    • (2006) J Infect Dis , vol.194 , pp. 486-492
    • Saliu, O.Y.1    Sofer, C.2    Stein, D.S.3
  • 46
    • 30744461133 scopus 로고    scopus 로고
    • TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo
    • Kim EY, Priatel JJ, Teh SJ, Teh HS. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 2006 ; 176 : 1026-35.
    • (2006) J Immunol , vol.176 , pp. 1026-1035
    • Kim, E.Y.1    Priatel, J.J.2    Teh, S.J.3    Teh, H.S.4
  • 47
    • 3543140687 scopus 로고    scopus 로고
    • Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy
    • Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004 ; 200 : 277-85.
    • (2004) J Exp Med , vol.200 , pp. 277-285
    • Ehrenstein, M.R.1    Evans, J.G.2    Singh, A.3
  • 48
    • 33646370647 scopus 로고    scopus 로고
    • TNF downmodulates the function of human CD4+CD25hi T-regulatory cells
    • Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006 ; 108 : 253-61.
    • (2006) Blood , vol.108 , pp. 253-261
    • Valencia, X.1    Stephens, G.2    Goldbach-Mansky, R.3
  • 49
    • 70350607858 scopus 로고    scopus 로고
    • Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists
    • Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006 ; 8 : R114.
    • (2006) Arthritis Res Ther , vol.8
    • Hamdi, H.1    Mariette, X.2    Godot, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.